A large population-based analysis of children with atopic dermatitis found only a small, clinically modest reduction in linear growth compared with peers without eczema, despite higher cumulative exposure to topical corticosteroids. The greatest differences were seen in those with more severe or persistent disease, but overall height-for-age remained largely within normal ranges. These findings help reassure clinicians and families that appropriate topical therapy, including steroids, is unlikely to meaningfully impair long-term growth when disease is well controlled. To learn more click here ##Reference ## Chen TL, Ma SH, Ou WF, Chen CC, Wu CY.
Decreased risk of reduced linear growth among children with atopic dermatitis receiving dupilumab: A cohort study. J Am Acad Dermatol. 2025;93(6):1471-1480.## In your experience, what is the main barrier to optimal topical corticosteroid use in…
